Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of IVX-A12 in Healthy Older Adults
NCT05664334Phase 1Completed
- Sponsor
- Icosavax, Inc.
- Start
- Sep 2022
- Primary completion
- Jan 2024
- Modality
- Recombinant Proteins and Enzymes, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of IVX-A12 in respiratory syncytial virus infection (RSV) and human metapneumovirus infection (HMPV) (6 arms), sponsored by Icosavax, Inc. Primary endpoints: Proportion of Participants With Solicited Local Reactions and Systemic Adverse Events, Proportion of Participants With Unsolicited Adverse Events and 2 more. Started Sep 2022; status: completed.
02
Drugs
IVX-A12
03
Conditions
respiratory syncytial virus infection (RSV)human metapneumovirus infection (HMPV)
Beyond the preview
Go deeper on NCT05664334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05664334.